Smadar Avigad

Summary

Affiliation: Tel Aviv University
Country: Israel

Publications

  1. doi request reprint Aberrant methylation and reduced expression of RASSF1A in Ewing sarcoma
    Smadar Avigad
    Molecular Oncology, Felsenstein Medical Research Center, Petah Tikva, Israel
    Pediatr Blood Cancer 53:1023-8. 2009
  2. doi request reprint Minimal residual disease in peripheral blood stem cell harvests from high-risk neuroblastoma patients
    Smadar Avigad
    Molecular Oncology, Felsenstein Medical Research Center, Tel Aviv University, Tel Aviv, Israel
    J Pediatr Hematol Oncol 31:22-6. 2009
  3. ncbi request reprint Prenatal diagnosis in Li-Fraumeni syndrome
    Smadar Avigad
    Molecular Oncology, Felsenstein Medical Research Center, Petah Tikva, Israel
    J Pediatr Hematol Oncol 26:541-5. 2004
  4. ncbi request reprint Association between telomerase activity and outcome in patients with nonmetastatic Ewing family of tumors
    A Ohali
    Department of Molecular Oncology, Felenstein Medical Research Center, Schneider Children s Medical Center of Israel, Petah Tikva, Israel
    J Clin Oncol 21:3836-43. 2003
  5. ncbi request reprint Short telomeres: a novel potential predictor of relapse in Ewing sarcoma
    Smadar Avigad
    Molecular Oncology, Felsenstein Medical Research Center, Petach Tikva, Israel
    Clin Cancer Res 13:5777-83. 2007
  6. ncbi request reprint The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors
    Smadar Avigad
    Department of Molecular Oncology, Felsenstein Medical Research Center, Petah Tikva, Israel
    Cancer 100:1053-8. 2004
  7. ncbi request reprint Germ-line ATM gene alterations are associated with susceptibility to sporadic T-cell acute lymphoblastic leukemia in children
    Ella Liberzon
    Molecular Oncology, Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Genes Chromosomes Cancer 39:161-6. 2004
  8. ncbi request reprint Telomere length is a prognostic factor in neuroblastoma
    Anat Ohali
    Molecular Oncology Laboratory, Felsenstein Medical Research Center, Rabin Medical Campus, Petah Tikva, Israel
    Cancer 107:1391-9. 2006
  9. ncbi request reprint High frequency of genomic instability in Ewing family of tumors
    Anat Ohali
    Molecular Oncology, Felsenstein Medical Research Center, Rabin Medical Campus, Sackler Faculty of Medicine, Tel Aviv University, 39 Jabotinski St, Petah Tikva 49100, Israel
    Cancer Genet Cytogenet 150:50-6. 2004
  10. pmc 2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics
    Marta Jeison
    Ca Cytogenetic Lab, Schneider Children s Medical Center of Israel, Kaplan St 14, 49202 Petah Tikva, Israel
    Am J Pathol 176:2616-25. 2010

Collaborators

  • Ian J Cohen
  • Shifra Ash
  • Batia Stark
  • Ron Ophir
  • Helen Toledano
  • Malka Gorfine
  • Ronit Abir
  • Shai Izraeli
  • Ziv Ben-Ari
  • Avi Ben-Haroush
  • E Fenig
  • Marta Jeison
  • D Meirow
  • L S Freedman
  • Anat Ohali
  • Isaac Yaniv
  • Drorit Luria
  • Rina Zaizov
  • Yacov Goshen
  • Ella Liberzon
  • Galina Feinberg-Gorenshtein
  • Josephine Issakov
  • Isaac Meller
  • Yehuda Kollender
  • A Ohali
  • Romy Zemel
  • Michal Armoni
  • Lina Wasserman
  • Burstein Yoav
  • Elhasid Ronit
  • Ninette Amariglio
  • Avrahami Gali
  • Miskin Hagit
  • Weintraub Michael
  • Yona Kodman
  • Kapelushnik Yosef
  • Marina Safanaiev
  • Gavriel Herzel
  • Attias Dina
  • Ballin Ami
  • Bielorai Bella
  • Eti Rosenthal
  • David Steinberg
  • Sthoeger Dalia
  • Jacques Mardoukh
  • Ran Steinberg
  • Gili Halevy-Berco
  • Avraham Weizman
  • Inna Naumov
  • Meora Feinmesser
  • Shirley Horn-Saban
  • Herzel Gavriel
  • Julia Zilberstein
  • Shalom Michovitz
  • Y Goshen
  • Y Kollender
  • R Zaizov
  • J Issakov
  • I Yaniv
  • I Meller
  • I Gelernter
  • David N Shapiro
  • Claud Koren
  • Gila Maor
  • Elimelech Okon
  • Chava Harel
  • Yosef Shaul
  • Ella Kaganovsky
  • Franklin Grief
  • Michael J Quon
  • Einat Beery
  • Yaacov Goshen
  • Larisa Bachmatove
  • Diana Esposito
  • Eddy Karnieli
  • Jardena Nordenberg
  • Ran Tur-Kaspa
  • Merav Ben-Yehoyada

Detail Information

Publications22

  1. doi request reprint Aberrant methylation and reduced expression of RASSF1A in Ewing sarcoma
    Smadar Avigad
    Molecular Oncology, Felsenstein Medical Research Center, Petah Tikva, Israel
    Pediatr Blood Cancer 53:1023-8. 2009
    ..However there is lack of similar broad based studies in ES. The objective of this study was to analyze RASSF1A methylation and assess its clinical significance in ES...
  2. doi request reprint Minimal residual disease in peripheral blood stem cell harvests from high-risk neuroblastoma patients
    Smadar Avigad
    Molecular Oncology, Felsenstein Medical Research Center, Tel Aviv University, Tel Aviv, Israel
    J Pediatr Hematol Oncol 31:22-6. 2009
    ..We investigated whether detection of minimal residual disease (MRD) in peripheral blood stem cells (PBSC) by using tyrosine hydroxylase (TH) expression could predict outcome of patients with advanced neuroblastoma...
  3. ncbi request reprint Prenatal diagnosis in Li-Fraumeni syndrome
    Smadar Avigad
    Molecular Oncology, Felsenstein Medical Research Center, Petah Tikva, Israel
    J Pediatr Hematol Oncol 26:541-5. 2004
    ..The authors addressed the complex question of predictive prenatal genetic testing for cancer risk associated with inheritance of TP53 mutation...
  4. ncbi request reprint Association between telomerase activity and outcome in patients with nonmetastatic Ewing family of tumors
    A Ohali
    Department of Molecular Oncology, Felenstein Medical Research Center, Schneider Children s Medical Center of Israel, Petah Tikva, Israel
    J Clin Oncol 21:3836-43. 2003
    ..The aim of this study was to determine telomerase activity (TA) as a prognostic factor at diagnosis and as a marker for minimal residual disease during therapy and follow-up in nonmetastatic Ewing family of tumors (EFT)...
  5. ncbi request reprint Short telomeres: a novel potential predictor of relapse in Ewing sarcoma
    Smadar Avigad
    Molecular Oncology, Felsenstein Medical Research Center, Petach Tikva, Israel
    Clin Cancer Res 13:5777-83. 2007
    ..Our aim was to evaluate whether telomere length could be a better prognostic factor in Ewing sarcoma and correlate the results with clinical variables, outcome, and chromosomal instability...
  6. ncbi request reprint The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors
    Smadar Avigad
    Department of Molecular Oncology, Felsenstein Medical Research Center, Petah Tikva, Israel
    Cancer 100:1053-8. 2004
    ..EFTs are characterized by specific chromosomal translocations that result in chimeric transcripts that can be detected with reverse transcriptase-polymerase chain reaction (RT-PCR) analysis...
  7. ncbi request reprint Germ-line ATM gene alterations are associated with susceptibility to sporadic T-cell acute lymphoblastic leukemia in children
    Ella Liberzon
    Molecular Oncology, Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Genes Chromosomes Cancer 39:161-6. 2004
    ....
  8. ncbi request reprint Telomere length is a prognostic factor in neuroblastoma
    Anat Ohali
    Molecular Oncology Laboratory, Felsenstein Medical Research Center, Rabin Medical Campus, Petah Tikva, Israel
    Cancer 107:1391-9. 2006
    ..The objective of this study was to evaluate telomere length and telomerase activity (TA) as markers for progression and prognosis in neuroblastoma...
  9. ncbi request reprint High frequency of genomic instability in Ewing family of tumors
    Anat Ohali
    Molecular Oncology, Felsenstein Medical Research Center, Rabin Medical Campus, Sackler Faculty of Medicine, Tel Aviv University, 39 Jabotinski St, Petah Tikva 49100, Israel
    Cancer Genet Cytogenet 150:50-6. 2004
    ..18). Our data suggest that GI may play a role in Ewing sarcoma clinical behavior and outcome...
  10. pmc 2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics
    Marta Jeison
    Ca Cytogenetic Lab, Schneider Children s Medical Center of Israel, Kaplan St 14, 49202 Petah Tikva, Israel
    Am J Pathol 176:2616-25. 2010
    ....
  11. doi request reprint Different telomere maintenance mechanisms in alveolar and embryonal rhabdomyosarcoma
    Anat Ohali
    Molecular Oncology, Felsenstein Medical Research Center, Petah Tikva, Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel
    Genes Chromosomes Cancer 47:965-70. 2008
    ..These findings have important implications for understanding the role of TMM in the development of RMS tumors, and for future designing adapted treatment strategies...
  12. ncbi request reprint Prediction of high risk Ewing's sarcoma by gene expression profiling
    Anat Ohali
    Molecular Oncology, Felsenstein Medical Research Center, Rabin Medical Campus, 39 Jabotinski Street, Petah Tikva 49100, Israel
    Oncogene 23:8997-9006. 2004
    ..Our results indicate the existence of a specific gene expression signature of outcome in ES already at diagnosis, and provide a strategy to select patients who would benefit from risk-adapted improved therapy...
  13. doi request reprint Reduced levels of miR-34a in neuroblastoma are not caused by mutations in the TP53 binding site
    Galina Feinberg-Gorenshtein
    Molecular Oncology, Felsenstein Medical Research Center, Petah Tikva, Israel
    Genes Chromosomes Cancer 48:539-43. 2009
    ..Thus, mutations in the binding site are not an additional mechanism for the inactivation of miR-34a in NB. Other regulatory mechanisms controlling miR-34a expression and its relationship to TP53 should be further explored...
  14. doi request reprint Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry
    Shifra Ash
    Department of Pediatric Hematology Oncology, Schneider Children s Medical Center of Israel, Petach Tikva, Israel
    Clin Cancer Res 17:2900-7. 2011
    ..Multiparameter flow cytometry (MPFC) was used to detect ES cells in bone marrow (BM) of ES patients at diagnosis and to evaluate the prognostic significance of CD56 expression in BM samples...
  15. ncbi request reprint ATM gene mutations are not involved in medulloblastoma in children
    Ella Liberzon
    Molecular Oncology, Felsenstein Medical Research Center, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel
    Cancer Genet Cytogenet 146:167-9. 2003
    ..The LOH in the 11q region may suggest hidden unidentified tumor suppressor genes that may be involved in the malignant transformation...
  16. doi request reprint Occasional involvement of the ovary in Ewing sarcoma
    Ronit Abir
    Infertility and IVF Unit, Helen Schneider Hospital for Women, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel
    Hum Reprod 25:1708-12. 2010
    ..Ovarian cryopreservation is often an option for fertility preservation in cancer patients of reproductive age, specifically in minors. Thus, the possibility of ovarian involvement in EWS needs to be elucidated...
  17. doi request reprint Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR)
    Batia Stark
    Center of Pediatric Hematology Oncology, Schneider Children s Medical Center of Israel, Petah Tiqwa, Israel
    Pediatr Blood Cancer 52:20-5. 2009
    ....
  18. doi request reprint Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia
    Drorit Luria
    Pediatric Hematology Oncology, Schneider Children s Medical Center of Israel, Israel
    Cytometry B Clin Cytom 78:365-71. 2010
    ..The influence of different techniques and of individual interpretation of data on the interlaboratory variability in FC-MRD determinations has not been described...
  19. ncbi request reprint Novel approaches for the management of patients with Ewing sarcoma
    Smadar Avigad
    Molecular Oncology, Felsenstein Medical Research Center, Schneider Children s Medical Center of Israel, Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel
    Future Oncol 2:659-65. 2006
    ....
  20. ncbi request reprint p73 overexpression and nuclear accumulation in hepatitis C virus-associated hepatocellular carcinoma
    Romy Zemel
    Molecular Hepatology Research Laboratory, Felsenstein Medical Research Center, Petach Tikva, Israel
    Dig Dis Sci 47:716-22. 2002
    ..In conclusion, p73 protein is overexpressed and accumulates in the nuclei of HCV-associated HCCs and may play a role in HCC development...
  21. ncbi request reprint The effect of aloe emodin on the proliferation of a new merkel carcinoma cell line
    Lina Wasserman
    Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Rabin Medical Center Beilinson Campus, Petah Tikva 49100, Israel
    Am J Dermatopathol 24:17-22. 2002
    ..Differentiation-inducing agents, and aloe emodin, merit further investigation as potential agents for treating MCC...
  22. ncbi request reprint PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro
    Michal Armoni
    Institute of Endocrinology, Diabetes and Metabolism, Rambam Medical Center, Technion Israel Institute of Technology, Haifa 31096, Israel
    J Clin Endocrinol Metab 87:5312-24. 2002
    ..Taken together, the data suggest that the GLUT4 gene is a downstream target of PAX3/FKHR and that GLUT4 is aberrantly transactivated by this oncoprotein both in vivo and in vitro...